Javier García‐Samaniego

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment

José M. Sánchez–Tapias, M. Diago, P Escartín et al. · Gastroenterology · 2006 · 360 citations

Hepatology, Hepatitis C, Versus 72 +8

Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study

Luz Martı́n-Carbonero, Yves Benhamou, Massimo Puoti et al. · Clinical Infectious Diseases · 2003 · 272 citations · Full text

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Stephen A. Harrison, Zachary Goodman, Abdul Jabbar et al. · Journal of Hepatology · 2019 · 240 citations

Rheumatology, Antifibrotic Therapy, Fibrosis +5